Menu Search
Equities

ADMA Biologics Inc

ADMA:NMQ

ADMA Biologics Inc

Actions
  • Price (USD)22.62
  • Today's Change2.90 / 14.71%
  • Shares traded9.72m
  • 1 Year change+524.86%
  • Beta0.7348
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year ADMA Biologics Inc grew revenues 67.59% from 154.08m to 258.22m while net income improved from a loss of 65.90m to a smaller loss of 28.24m.
Gross margin46.12%
Net profit margin10.53%
Operating margin17.49%
Return on assets9.67%
Return on equity20.77%
Return on investment10.99%
More ▼

Cash flow in USDView more

In 2023, cash reserves at ADMA Biologics Inc fell by 35.17m. However, the company earned 8.80m from its operations for a Cash Flow Margin of 3.41%. In addition the company used 4.98m on investing activities and also paid 38.99m in financing cash flows.
Cash flow per share0.184
Price/Cash flow per share123.92
Book value per share0.8079
Tangible book value per share0.7907
More ▼

Balance sheet in USDView more

ADMA Biologics Inc has a Debt to Total Capital ratio of 41.05%, a lower figure than the previous year's 95.60%.
Current ratio6.87
Quick ratio2.80
Total debt/total equity0.6962
Total debt/total capital0.4105
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.